MedTrace Logo

Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in NSCLC Cachexia

NCT02515032 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2017-07-17

No results posted yet for this study

Summary

SF-C002 is a pilot study in patients with newly diagnosed NSCLC suffering from involuntary weight loss. The study is 12 weeks, double-blinded, placebo controlled and the main objective is to study the safety and tolerability of Nutrifriend Cachexia.

Conditions

Interventions

DIETARY_SUPPLEMENT

Nutrifriend Cachexia

2 daily for 12 weeks

DIETARY_SUPPLEMENT

Isocaloric placebo

2 daily for 12 weeks

Sponsors & Collaborators

  • Smartfish AS

    lead INDUSTRY

Principal Investigators

  • Maurizio Muscaritoli, Prof. · University Hospital Sapienza

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • Croatia
  • Italy
  • Slovakia
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02515032 on ClinicalTrials.gov